Alternative splicing of proteins gives rise to an untapped wealth of tissue and disease-specific variants.
Isoform Oncology is exploiting isoform switching and alternative splicing for the development of new cancer biotherapeutics – designed to keep precision-medicine on target.
Splicing of RNA means that each of our genes can code for several protein variations.
This is important in the different tissues of our bodies, giving rise to protein isoforms that are optimised for different functions.
This goes wrong in cancer.
We identify cancer-specific isoforms of common proteins.
We use these unique targets to attack and kill cancer cells.
Our therapeutics are carefully selected so that they will work when traditional treatments have failed or cancer cells have become resistant.
Some patients do not have the "right cancer" to be eligible for blockbuster treatments. We want a future where no patient has to miss out.
We are developing a pipeline of isoform-targeting medicines to tackle some of the most important cancers where there remains an unmet need.
Larcombe
CEO co-founder
Experienced founder. Computational biologist, BSc in genetics, PhD in synthetic antigen design for antibody development.
Morgan
CSO co-founder
Translational biologist, BSc and MSc in biomedical science, MA in healthcare law & ethics, PhD in variant splice targets in cancer.
Moll
Scientific Advisor
Industry leader in oncology drug discovery. Boehringer-Ingelheim, Sanofi, Pfizer.
Patients deserve precise and effective medicines that work:
On target. On time. Every time.